Isoray, Inc. provided sales guidance for the first quarter ending September 30, 2022. In the short term, although the company don't have adequate supply now of Cesium-131, the company expects a decline in sales in the first fiscal quarter of 2023 ending September 30, 2022, versus the prior year. The company currently anticipates total revenue for this period to be between $1.6 million and $1.8 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.07 USD | -7.76% |
|
-10.83% | +166.17% |
Jun. 12 | Sector Update: Health Care Stocks Ease Late Afternoon | MT |
Jun. 12 | Sector Update: Health Care Stocks Softer Wednesday Afternoon | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+166.17% | 721M | |
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- CATX Stock
- News Perspective Therapeutics, Inc.
- Isoray, Inc. Provides Sales Guidance for the First Quarter Ending September 30, 2022